

Name of the Issue: Mankind Pharma Limited

Last Updated on: 16-Nov-2025

1 Type of Issue (IPO/FPO) IPO

2 Issue Size (Rs. Cr) 43,263.55*
* As per Basis of Allotment

3 Grade of issue alongwith name of the rating agency
Name Not Applicable
Grade Not Applicable

4 Subscription Level (Number of times): 15.4631*
* Based on valid applications (excluding Anchor investors, duplicate and multiple bids)
Source: Minutes of Basis of Allotment dated May 03, 2023

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) allotment in the issue*	5.28%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (June 30, 2023)	8.82%
(iii) at the end of 2nd FY (March 31, 2024)	21.01%
(iv) at the end of 3rd FY (March 31, 2025)	24.40%
(v) at the end of 3rd FY (March 31, 2026)#	Not Available

* As per the Basis of Allotment dated May 03, 2023
QIB Holding not disclosed as reporting for relevant period / fiscal years have not been completed/ not publicly available
Source: Basis of allotment, as reported to stock exchanges, BSE and NSE

6 Financials of the issuer (as per the annual financial results submitted to stock exchanges)
(Rs. Crore)

Parameters (Consolidated)	1st FY (March 31, 2024)	2nd FY (March 31, 2025)	3rd FY (March 31, 2026) ⁽¹⁾
Income from operations	10,260.4	12,207.4	Not Available
Net Profit for the period	1,941.8	2,011.1	Not Available
Paid-up equity share capital	40.1	41.3	Not Available
Reserves excluding revaluation reserves	9,323.0	14,291.1	Not Available

⁽¹⁾ Financials not disclosed as reporting for the fiscal year has not been completed/ not publicly available

7 Trading Status in the scrip of the issuer
Company's Equity Shares are listed on both, the BSE Limited and the National Stock Exchange of India Limited.
The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2025)	Frequently traded
(iii) at the end of 3rd FY (March 31, 2026)*	Not Applicable

* Trading status not disclosed as the relevant fiscal year has not been completed.

8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)	Mr Leonard Lee Kim	Resigned
(ii) at the end of 2nd FY (March 31, 2025)	Mr. Surendra Lunia	Resigned
(iii) at the end of 3rd FY (March 31, 2026)*	-	-
	Not Available	Not Available

As per the website of BSE and NSE

* Changes in Directors not disclosed as the relevant fiscal year has not been completed.

9 Status of implementation of project/ commencement of commercial production

- (i) as disclosed in the offer document - Not applicable as 100% OFS
(ii) Actual implementation - Not Applicable
(iii) Reasons for delay in implementation, if any - Not Applicable

10 Status of utilization of issue proceeds

- (i) as disclosed in the offer document - Not applicable as 100% OFS
(ii) Actual utilization - Not applicable
(iii) Reasons for deviation, if any - Not Applicable

11 Comments of monitoring agency, if applicable

Not Applicable

12 Pricing Data

Issue Price (Rs.): 1,080
Designated Stock Exchange: NSE
Listing Date: 9-May-23

Price parameters	At close of listing day (9-May-2023)	At close of 30th calendar day from listing day ⁽¹⁾	At close of 90th calendar day from listing day ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2024) ⁽³⁾		
				Closing price	High (during the FY)	Low (during the FY)
Market Price (on NSE)	1,422.30	1,486.15	1,880.60	2,300.8	2,366.4	1,242.0
Nifty 50	18,265.95	18,726.40	19,517.00	22,326.90	22,526.60	17,312.75
Sectoral Index	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2025) ⁽³⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2026) ^(3,4)		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price (on NSE)	2,424.8	3,054.8	1,901.1	N.A	N.A	N.A
Nifty 50	23,519.4	26,277.4	21,281.5	N.A	N.A	N.A
Sectoral Index	N.A	N.A	N.A	N.A	N.A	N.A

Source: NSE Website

⁽¹⁾ 30th calendar day has been taken as listing date plus 29 calendar days, except where 30th calendar day is a holiday, in which case we have considered the closing data of the previous trading day

⁽²⁾ 90th calendar day has been taken as listing date plus 89 calendar days, except where 90th calendar day is a holiday, in which case we have considered the closing data of the previous trading day

⁽³⁾ High and Low based on intra day prices

⁽⁴⁾ Pricing data not disclosed as the relevant fiscal year has not completed

13 Basis for Issue Price

Accounting ratio		As disclosed in the prospectus dated April 28, 2023 ⁽¹⁾	At the end of 1st FY (March 31, 2024)	At the end of 3rd FY (March 31, 2025)	At the end of 3rd FY (March 31, 2026) ⁽²⁾
Diluted EPS (Rs.)	Issuer*:	35.78	47.68	49.20	Not Available
	Peer Group & Industry Average**:	78.00	91.91	107.78	Not Applicable
	Sun Pharmaceuticals Industries Limited	13.60	39.91	45.60	Not Applicable
	Cipla Limited	31.17	51.01	65.24	Not Applicable
	Zydus Lifesciences Limited	43.83	38.14	44.97	Not Applicable
	Torrent Pharmaceutical Limited	22.97	48.94	56.47	Not Applicable
	Alkem Laboratories ⁽²⁾	137.63	150.19	N/A	Not Applicable
	JB Chemicals & Pharmaceuticals Limited	49.82	34.85	41.56	Not Applicable
	Eris Lifesciences Limited	29.88	28.79	25.81	Not Applicable
	Ipca Laboratories Limited ⁽²⁾	34.85	21.57	N/A	Not Applicable
	Abbott India Limited	375.86	565.30	665.62	Not Applicable
	Glaxosmithkline Pharmaceuticals Limited	100.04	34.83	54.76	Not Applicable
	Dabur India Limited	9.81	10.38	9.95	Not Applicable
	Procter & Gamble Health Limited	116.00	128.93	121.08	Not Applicable
	Zydus Wellness Limited	48.54	41.94	54.52	Not Applicable
P/E(x)	Issuer*:	30.18***	48.11	49.25	Not Available
	Peer Group & Industry Average**:	40.16	41.69	41.09	Not Applicable
	Sun Pharmaceuticals Industries Limited	71.54	40.60	38.06	Not Applicable
	Cipla Limited	28.18	29.28	22.08	Not Applicable
	Zydus Lifesciences Limited	10.95	26.36	19.70	Not Applicable
	Torrent Pharmaceutical Limited	66.25	53.15	57.28	Not Applicable
	Alkem Laboratories ⁽²⁾	23.03	32.89	NA	Not Applicable
	JB Chemicals & Pharmaceuticals Limited	39.48	46.25	38.21	Not Applicable
	Eris Lifesciences Limited	19.10	29.19	54.80	Not Applicable
	Ipca Laboratories Limited ⁽²⁾	22.38	57.39	NA	Not Applicable
	Abbott India Limited	56.19	47.67	46.17	Not Applicable
	Glaxosmithkline Pharmaceuticals Limited	57.03	55.80	52.54	Not Applicable
	Dabur India Limited	54.55	50.31	50.81	Not Applicable
	Procter & Gamble Health Limited	42.27	37.97	41.71	Not Applicable
	Zydus Wellness Limited	31.11	35.07	30.66	Not Applicable

RoNW (%)	Issuer*	23.29	19.93	13.80	Not Available
	Peer Group & Industry Average**:	21.78	18.55	22.35	Not Applicable
	Sun Pharmaceuticals Industries Limited	6.82	14.27	15.08	Not Applicable
	Cipla Limited	12.08	15.38	16.85	Not Applicable
	Zydus Lifesciences Limited	26.40	17.36	17.17	Not Applicable
	Torrent Pharmaceutical Limited	13.06	24.16	25.17	Not Applicable
	Alkem Laboratories ⁽²⁾	19.05	16.72	NA	Not Applicable
	JB Chemicals & Pharmaceuticals Limited	18.06	18.89	19.21	Not Applicable
	Eris Lifesciences Limited	21.28	12.16	10.75	Not Applicable
	Ipca Laboratories Limited ⁽²⁾	16.10	7.08	NA	Not Applicable
	Abbott India Limited	28.32	32.48	33.41	Not Applicable
	Glaxosmithkline Pharmaceuticals Limited	63.64	33.19	47.54	Not Applicable
	Dabur India Limited	20.75	17.88	15.77	Not Applicable
	Procter & Gamble Health Limited ⁽³⁾	31.23	26.56	38.75	Not Applicable
	Zydus Wellness Limited	6.38	4.98	6.12	Not Applicable
	NAV per share based on last balance sheet	153.65	239.62	353.08	Not Available
	Peer Group & Industry Average**:	368.06	453.35	460.57	Not Applicable
	Sun Pharmaceuticals Industries Limited	200.10	279.69	302.11	Not Applicable
	Cipla Limited	258.32	332.01	387.43	Not Applicable
	Zydus Lifesciences Limited	166.05	219.66	261.95	Not Applicable
	Torrent Pharmaceutical Limited	175.89	202.61	224.29	Not Applicable
	Alkem Laboratories ⁽²⁾	722.44	898.28	NA	Not Applicable
	JB Chemicals & Pharmaceuticals Limited	240.83	188.47	220.54	Not Applicable
	Eris Lifesciences Limited	140.39	236.97	240.28	Not Applicable
	Ipca Laboratories Limited ⁽²⁾	216.47	304.57	NA	Not Applicable
	Abbott India Limited	1,327.00	1,740.71	1,992.14	Not Applicable
	Glaxosmithkline Pharmaceuticals Limited	157.19	104.93	115.19	Not Applicable
	Dabur India Limited	47.41	58.14	63.25	Not Applicable
	Procter & Gamble Health Limited ⁽³⁾	371.39	485.46	367.79	Not Applicable
	Zydus Wellness Limited	761.26	842.06	891.31	Not Applicable

Source:

* All the financial information for the Company above is on a restated and consolidated basis.

** All the financial information for listed industry peers mentioned above is on a consolidated basis (unless otherwise available only on standalone basis) and is sourced from the financial statements of the respective company for the fiscal year ended March 31

*** P/E Ratio for the Company has been computed based on the Offer Price of ₹ 1,080 per Equity Share divided by the Diluted EPS as at March 31, 2022.

Notes:

⁽¹⁾ Sourced from Prospectus dated April 28, 2023.

⁽²⁾ Information not provided as the relevant fiscal year has not completed or data not available

⁽³⁾ For Procter & Gamble Health Limited the latest B/S is for the year ended December year end Accordingly, RoNW and NAV pertain to year ended December year end

14 **Any other material information**

Particulars	Date
Execution of Business Transfer Agreement between Mankind Pharma Limited and Bharat Serums & Vaccines Limited (a Wholly Owned Subsidiary)	10-Oct-25
Mankind Pharma Limited ("Company") has executed a Business Transfer Agreement ("BTA") with Bharat Serums and Vaccines Limited ("BSV"), a Wholly Owned Subsidiary Company, on October 10, 2025 for acquisition of its Branded Generic Business relating to Women Health Rx Portfolio on going concern basis by way of slump sale for a sale consideration of ₹797 Crores, subject to closing adjustments, payable in the following manner: 1. 50% of the sale consideration shall be paid on the Closing Date as defined in the BTA; and 2. Balance sale consideration shall be payable within 150 days from the Closing Date	
Re-classification of Ayushi and Poonam Estates LLP form "Promoter & Promoter Group" to "Public" Category of Mankind Pharma Limited ("the Company")	2-Sep-25
Company has received approval from both BSE and NSE for such re-classification in accordance with the provisions of Regulation 31A of the Listing Regulations on September 2, 2025.	
Incorporation of a Wholly Owned Subsidiary Company in Russia	19-Aug-25
Proposed wholly owned subsidiary has been incorporated in Russia on August 18, 2025 (intimation of the same was received today i.e. August 19, 2025) under the name and style of "Mankind Pharma LLC"	
Intimation regarding appointment of Secretarial Auditors	8-Aug-25
The shareholders of the Company, at the 34th Annual General Meeting held on Thursday, August 07, 2025, have, inter alia, approved the appointment of M/s. Amit Gupta & Associates, Company Secretaries, as the Secretarial Auditors of the Company for a term of five 5 years	
Intimation of incorporation of a Wholly Owned Subsidiary Company in Sri Lanka	24-Jul-25
Wholly owned subsidiary has been incorporated in Sri Lanka on July 23, 2025 (intimation of the same was received today i.e. July 24, 2025) under	
Intimation of incorporation of a Wholly Owned Subsidiary Company	2-Jun-25
Wholly owned subsidiary under Section 8 of the Companies Act, 2013 has been incorporated on June 2, 2025 under the name and style of KINDCARE FOUNDATION ("WOS").	
Release of Pledge on the shares of Bharat Serums and Vaccines Limited	2-May-25
As per terms and conditions of Debenture Trust Deeds, the security cover provided for the NCDs was in excess of the mandatory threshold as prescribed under the Debenture Trust Deeds and accordingly, out of the total 95.99% equity shares of BSV pledged as aforesaid, equity shares representing 57.31% have been released	
Outcome of Board meeting	14-Apr-25
Board of Directors of the Company has considered and approved the, (a) Constitution of a 'Structural Integration Committee' to consider and evaluate various structural alternatives to integrate Bharat Serums and Vaccines Limited ("BSV") into Mankind Pharma Limited's ("Company") eco system ("Proposed Structural Integration") (b) Incorporation of a wholly owned subsidiary, directly or indirectly, in Russia ("Foreign WOS") (c) Incorporation of a wholly owned subsidiary under Section 8 of the Companies Act, 2013 ("Indian WOS") for undertaking CSR activities of the Mankind Group.	
Amalgamation of BSV Pharma Private Limited, Step Down Subsidiary with Bharat Serums and Vaccines Limited, Material Subsidiary of the Company	29-Mar-25
Effective date of the Scheme of Arrangement for Amalgamation amongst Shree Jee Laboratory Private Limited ("Transferor Company 1"), JPR Labs Private Limited ("Transferor Company 2") and Jaspack Industries Private Limited ("Transferor Company 3") with Mankind Pharma Limited ("Transferee Company"/ "the Company") is March 29, 2025	
Amalgamation of BSV Pharma Private Limited, Step Down Subsidiary with Bharat Serums and Vaccines Limited, Material Subsidiary of the Company	28-Mar-25
National Company Law Tribunal, Mumbai Bench, (NCLT) in its hearing held today i.e. March 28, 2025 approved the Scheme of Amalgamation ("Scheme") of BSV Pharma Private Limited (Transferor Company), step down subsidiary with Bharat Serums and Vaccines Limited (Transferee Company), Material Subsidiary of Mankind Pharma Limited (the "Company") and their respective shareholders under Sections 230 and 232 of the Companies Act, 2013 read with rules framed thereunder.	
	27-Feb-25
Pronouncement of Order by the Hon'ble NCLT Delhi Bench sanctioning the of Scheme of Arrangement for Amalgamation	
National Company Law Tribunal, New Delhi Bench (NCLT), has approved the Scheme of Arrangement for Amalgamation of Shree Jee Laboratory Private Limited ("Transferor Company 1"), JPR Labs Private Limited ("Transferor Company 2") and Jaspack Industries Private Limited ("Transferor Company 3") with Mankind Pharma Limited ("Transferee Company"/ "the Company") and their respective shareholders and creditors ("Scheme"/ "Scheme of Arrangement"), under Sections 230 and 232 of the Companies Act, 2013 read with rules framed thereunder. The Appointed Date for the approved Scheme of Arrangement is April 01, 2024	
	18-Feb-25
Second consecutive term of Mr. Surendra Lunia as an Independent Director of the Company completed on February 18, 2025, consequently, he ceases to be an Independent Director of the Company, effective from the close of business hours on February 18, 2025.	
Sale of entire stake in Mahananda Spa and Resorts Private Limited	10-Feb-25

<p>Outcome of the Board Meeting held on January 8, 2025</p> <p>Resignation of Mr. Ashish Mittal from the position of Company Secretary and Compliance Officer of the Company w.e.f. the close of business hours on January 8, 2025, as part of internal re-structuring. Mr. Mittal will continue to work with the Company at his earlier position i.e. Assistant General Manager- Secretarial</p> <p>Appointment of Mr. Hitesh Kumar Jain (ICSI Membership No. F6241) as Company Secretary and Compliance officer of the Company and Key Managerial Personnel w.e.f. January 9, 2025, as recommended by Nomination and Remuneration Committee</p> <p>Mr. Prakash Agarwal, President – Strategy has been designated as Senior Management Personnel (“SMP”) of the Company</p>	8-Jan-25
<p>Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011</p> <p>The promoters' and promoters' group's shareholding has diluted from 74.87% to 72.71%, reflecting a reduction of 2.16%.</p>	26-Dec-25
<p>Qualified Institutions Placement of Equity Shares of face value of ₹1 each</p> <p>Raising of funds aggregating up to ₹ 3,000 crores (Indian Rupees Three Thousand Crores only) by way of Qualified Institutions Placement (“QIP”) under applicable laws, including the Companies Act, 2013 read with the rules notified thereunder and Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, by way of issuance of such number of equity shares having a face value of ₹ 1 each of the Company;</p>	16-Dec-25
<p>Outcome of Board Meeting held on December 3, 2024</p> <p>Appointment of Mr. Ashish Mittal (ICSI Membership No. A25169) as Company Secretary and Compliance officer of the Company and Key Managerial Personnel and designated as Deputy Company Secretary with effect from December 3, 2024, as recommended by Nomination and Remuneration Committee</p>	3-Dec-25
<p>Intimation that Company has received an Order on 22 November 2024 from Office of the Principal Commissioner, CGST, Meerut – issued by Additional Commissioner (“Department”) under Section 74 of the CGST Act, 2017.</p> <p>Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received an Order on 22 November 2024 from Office of the Principal Commissioner, CGST, Meerut – issued by Additional Commissioner (“Department”) under Section 74 of the CGST Act, 2017. Based on the assessment of facts and prevailing law, the Company is of the view that the aforesaid order is arbitrary and unjustified. [penalty of INR 290,70,363/- is being imposed.]</p>	22-Nov-24
<p>Intimation that Company has received an Order on 22 November 2024 from Office of the Principal Commissioner, CGST, Meerut – issued by Additional Commissioner (“Department”) under Section 74 of the CGST Act, 2017.</p> <p>Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received an Order on 22 November 2024 from Office of the Principal Commissioner, CGST, Meerut – issued by Additional Commissioner (“Department”) under Section 74 of the CGST Act, 2017. Based on the assessment of facts and prevailing law, the Company is of the view that the aforesaid order is arbitrary and unjustified. [penalty of INR 290,70,363/- is being imposed.]</p>	22-Nov-24
<p>Intimation under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Creation of Pledge on the shares of Bharat Serums and Vaccines Limited</p> <p>Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that as per the terms and conditions of 3 Debenture Trust Deeds executed on October 10, 2024 between the Catalyst Trusteeship Limited and the Company for the issuance of listed, rated, secured, redeemable, transferable non-convertible debentures aggregating to INR 5,000 crores (“NCDs”) by the Company in 3 Series, 39.68% equity shares of Bharat Serums and Vaccines Limited, wholly owned subsidiary of the Company (“BSV”) have been pledged in favour of Catalyst Trusteeship Limited as the Common Security Trustee for the benefit of the holders of the NCDs</p>	15-Nov-24
<p>Outcome of Board Meeting held today i.e. November 5, 2024</p> <p>- Signed audited financial results of the Company for the quarter and half year ended on September 30, 2024 along with Limited Review Report</p> <p>- Appointment of Ms. Vijaya Sampath as Independent Director on the Board of Bharat Serums and Vaccines Limited (“BSV”), Material subsidiary of the Company</p> <p>- Alteration of Articles of Association of the Company by inserting a new article to authorize Debenture Trustee(s) to nominate a person to be appointed as a director on the Board of the Company</p> <p>- Increasing the limits for creation of Mortgage and/or charge on all or any of the movable and/or immovable properties of the Company under Section 180(1)(a) and other applicable provisions of the Companies Act, 2013,</p> <p>- Pledge of the equity shares of Bharat Serums and Vaccines Limited, material wholly owned subsidiary of the company, subject to the approval of the Members of the Company.</p> <p>- Mr. Pradeep Chugh, Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company, has submitted his resignation to pursue career opportunity outside the Organization</p>	5-Nov-24

Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 – Final update in relation to the acquisition of 100% stake in Bharat Serums and Vaccines Limited	23-Oct-24
The Board of Directors of the Company at its meeting held on September 20, 2024, has inter-alia, considered and approved raising of funds by way of issuance of Non-Convertible Debentures ("NCDs") and Commercial Papers ("CPs") on private placement basis for an amount aggregating upto INR 10,000 crores (Rupees Ten Thousand crores only).	20-Sep-24
Intimation of Signing of Business Transfer Agreement with Wholly Owned Subsidiary Company	3-Sep-24
the Company has executed the Business Transfer Agreement ("BTA") on September 3, 2024 to transfer Over the Counter (OTC) Business Undertaking (defined in the BTA) of the Company as a going concern on a slump sale basis to Mankind Consumer Products Private Limited (MCPPL), a wholly owned subsidiary of the Company	
The Board of Directors of the Company at its meeting held on July 25, 2024, considered and approved the acquisition of 100% stake in Bharat Serums and Vaccines Limited (BSV) subject to completion of customary conditions and receipt of requisite regulatory approvals pursuant to the terms and conditions of (a) the Share Purchase Agreement dated July 25, 2024 amongst the Company, BSV and the sellers i.e. Ansamira Limited and Miransa Limited, Affiliates of funds managed by Advent International, and (b) Share Purchase Agreement dated July 25, 2024 amongst Company, BSV and certain minority shareholders i.e. Bhaskar Iyer and Abhijit Mukherjee (collectively referred as "Share Purchase Agreements").	25-Jul-24
Outcome of Board meeting	15-May-23
Board of directors approved: (i) Increase the authorized share capital of the company from INR 41.35cr to INR 60 cr	
Allotment of 46,698 Equity Shares under Mankind Pharma Limited Employee Stock Option Plan 2022	10-May-24
Outcome of Board meeting	2-Apr-23
Board of directors approved slump sale of the Over the Counter ("OTC") Business of the Company to Wholly Owned Subsidiary Company proposed to be incorporated with the name of Mankind Consumer Products Private Limited or any other name as approved by Ministry of Corporate Affairs	
Receipt of approval for reclassification of shareholding from "Promoter & Promoter Group" category to "Public" category under Regulation 31A	5-Mar-23
Company received approval from BSE and NSE regarding reclassification of EzeRx Health Tech Private Limited from "Promoter and Promoter Group" Category to "Public" Category	
Sale of certain equity shares of the face value of Rs. 1 each held by Mr. Sheetal Arora, Mr. Arjun Juneja and Mrs. Puja Juneja, Promoter and Promoter Group members of the Company in the open market for achieving minimum public shareholding	7-Feb-24
Sale of equity shares of Mankind Pharma Limited by Beige Limited and Link Investment Trust	18-Dec-23
Pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (" SEBI Takeover Regulations "), Company informed that Beige Limited and Link Investment Trust collectively sold 1,80,00,000 equity shares of Mankind Pharma Limited by way of an open market sale	
Investment in Actimed Therapeutics Limited	15-Dec-23
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), Company informed that it has made investment of GBP 999,900 in Actimed Therapeutics Limited ("Actimed") on December 15, 2023	
Change in Senior Management Personnel	16-Oct-23
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Para A of Part A of Schedule III to the Listing Regulations, Company informed that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company vide Circular Resolution passed on 16th October 2023, approved the appointment of Mr. Prateek Dubey as President – Global Chief Human Resource Officer (being Senior Management Personnel) w.e.f. October 16, 2023	
Intimation of resumption of operations at the Company's manufacturing facility at Sikkim	13-Oct-23
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Para B of Part A of Schedule III to the Listing Regulations and in continuation to Company's letter dated October 5, 2023 regarding disruptions of operations at the Company's manufacturing facility at Daring Block, Berinok, Namchi Zilla, South Sikkim ("Sikkim manufacturing facility") due to disturbance in power/utility supply because of flash floods. Compay informed that Sikkim manufacturing facility has resumed its operations as usual with effect from October 13, 2023	
Intimation of Commencement of Commercial Operations at Udaipur Plant	25-Sep-23
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Para B of Part A of Schedule III to the Listing Regulations, Company informed that the commercial operations with respect to pharmaceutical formulations has commenced at the Company's newly set-up plant in Udaipur, Rajasthan with effect from today i.e. September 25, 2023	

Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("the Listing Regulations")	17-May-23
Income Tax Department ("IT Dept") conducted search under the Income Tax Act, 1961 at some of the offices and plants of the Company and its subsidiaries. The company cooperated with the officials of IT Dept during the proceedings and responded to the clarifications and details sought by them. The business operations of the Company continue as usual and have not been impacted due to the search	
Change in Director: Disclosure under Regulation 30 of the Securities and Exchange Roard of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("the Listing-Regulations")	9-May-23
Mr. Leonard Lee (DIN: 07379167) a director representing CIPEF and CGPE on the Board of Directors of the Company has tendered his resignation with effect from 9th May 2023	
Listing of equity shares of Mankind Pharma Limited	9-May-23

Source: Stock Exchange filings; For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com